ENO1 expression is significantly upregulated in all kinds of malignancies, ranging from glioma, nasal laryngeal carcinoma, mammary cancer, and pancreatic cancer to uterine cancer, etc. Studies have found that in pancreatic cancer, the expression of ENO1 is positively correlated with clinical stage and lymphatic metastasis and negatively correlated with survival time [7]. Here, ENO1 is linked to familial pancreatic carcinoma.